Safety and efficacy of glecaprevir/pibrentasvir combination therapy for hepatitis C infected patients with chronic hepatitis or liver cirrhosis
Not Applicable
- Conditions
- patients with HCV infection
- Registration Number
- JPRN-UMIN000031090
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a past history of hypersensitivity to HCV protease inhibitors and NS5A inhibitors 2)Patients with serious liver dysfunction (Child-Pugh Class B or C) 3)Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4)Patients who have malignant tumors, including hepatoma, at the start of treatment 5)Patients on treatment with drugs listed in the contraindications for coadministration in thepackage insert (e.g., some antifungals, some antiepileptics, and human immunodeficiency virus (HIV) protease inhibitors) 6)Other patients judged to be inappropriate to participate in the study by the primary physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method